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Abstract
Background: This study identified per patient resource use and staff costs at a cystic fibrosis (CF) outpatient unit
from the health care provider’s perspective.
Methods: Personnel cost data were prospectively collected for all CF outpatients (n = 126) under routine
conditions at the Charité Medical School Berlin in Germany over a six month study period. Patients were grouped
according to age, sex and two severity categories. Ordinary least squares regression analysis was performed to
determine the impact of various independent variables on personnel costs.
Results: The mean staff costs were €142.3 per patient over six months of outpatient service. Services provided by
physicians were the biggest contributor to staff costs. Patient age correlated significantly and negatively with mean
total costs per patient.
Conclusions: Age of patient is a significant determinant of staff costs for CF outpatient care. For a cost-covering
remuneration of outpatient treatment it seems plausible to create separate reimbursement rates for two or three
age groups and to consider additional costs due to tasks carried out by physicians without direct patient contact.
The relatively low staff costs identified by our study reflect a staffing level not sufficient for specialist CF outpatient
care.
Keywords: Cystic fibrosis, outpatient service, cost analysis, micro-costing, activity-based costing, respiratory tract
colonization, lung function testing, analysis of variance, multivariate analysis
Background
Cystic fibrosis (CF) is the commonest life-threatening
genetic disease occurring in approximately 1/3500 white
newborns [1]. This autosomal recessive disorder is char-
acterised by chronic endobronchial bacterial infection
and neutrophil mediated inflammation leading to pro-
gressive pulmonary deterioration, respiratory failure and
premature death [2]. Other clinical consequences
include pancreatic insufficiency, liver disease that may
progress to cirrhosis, gut motility problems and elevated
sweat electrolytes. CF-patients need an intensive, holistic
and life-long treatment provided by specialist care [3,4].
The management of CF is an expensive commitment
on the part of health care providers and those who fund
them. Costs of care for patients with CF are rising as a
result of new medical interventions that improve health
status and life expectancy. In the United States of Amer-
ica (USA), the median age of survival for CF patients, i.
e. the age at which half of the current population with
CF would be expected to survive, has risen to 35.9 years
in 2009, up from 27 years in 1985, 14 years in 1969, and
5 years in 1955 [5]. With enhanced screening and
implementation of new therapies the predicted median
survival for newborns in 2000 with CF is likely more
than 50 years [6]. As a consequence of improved prog-
nosis this complex inherited disease will have consider-
able implications on the resources required for case
management.
In Germany, outpatient treatment for most of the
8000 CF patients is provided by about 110 hospital-
based CF reference centres [7]. Given the complexity of
the disease, the centres comprise variable numbers of
specialist CF physicians and nurses, dietitians, phy-
siotherapists and psychologists. These health
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professionals follow defined standards for the evaluation,
monitoring and treatment of CF outpatients including
surveillance of pulmonary function and bacterial coloni-
sation status, early management of infection, education
on inhalation and airways clearance techniques, assess-
ment of and advice on nutritional status, as well as psy-
chological support for patients and their families.
Comparative data suggest that the care provided in CF
reference centres substantially improves patients’ well
being and quality of life [8]. However, staff levels at CF
centres in Germany are far below those recommended
by the European Consensus Conference [9]. A recent
study conducted by the German CF association found
that only about 50% of the costs for hospital-based out-
patient care are reimbursed by the public health insur-
ance system, while the remaining costs are usually
borne by the hospitals [10].
Several studies have been published on hospitalization
costs or cost-of-illness of cystic fibrosis [8,11-22]. How-
ever, to date only few studies have conducted a detailed
cost analysis for outpatients [8,9]. Moreover, most stu-
dies calculating the costs of CF are based on a gross-
costing approach. Only two studies used a micro-costing
approach in calculating costs of hospital and outpatient
care, respectively [15,23]. Such information is important
for understanding the true costs of all components of
CF treatment and underlying reasons for variation in
costs. The present study provides a detailed activity-
based analysis of the actual use of health personnel,
which is usually perceived as a major cost factor in out-
patient care. Given the identification of wide interindivi-
dual variation in disease severity and hospitalization
costs for patients with CF [15,17,18,20,22], we hypothe-
sized that staff costs for outpatient care vary with
patient-related characteristics.
To aid public health policy makers in their efforts to
ensure a financial coverage for CF outpatient care that
is commensurate with the actual expenses, we under-
took a prospective study with the following objectives:
(1) to identify per patient average resource use and
costs for personnel at a CF outpatient centre from the
health care provider’s perspective; (2) to assess whether
outpatients can be grouped into cost homogenous clus-
ters of patients according to sex, age group, and disease
severity levels; (3) to evaluate the value of demographic
and clinical variables in predicting staff costs.
Methods
Study subjects
Our prospective study on health personnel utilization
and determinants of staff costs in hospital-based outpa-
tient CF care was carried out between January and June
2004. All patients (n = 126) who attended the CF outpa-
tient unit of the Department for Pediatric Pneumology
and Immunology at the Charité Medical School Berlin
in Germany during this period were enrolled. We
assumed that this time frame provided a representative
mix of CF patients undergoing routine check-ups at the
outpatient centre.
Data collection
The following data were collected for all patients that
visited the CF outpatient centre during the study period:
patient age, sex, clinical parameters, and use of staff.
The clinical data included respiratory tract colonization
by Pseudomonas aeruginosa, respiratory insufficiency
and forced expiratory volumes in one second (FEV1).
Personnel costs directly incurred by each outpatient
were prospectively collected for all visits under routine
conditions by using a micro-costing approach. There are
pros and cons for using micro-costing versus gross-cost-
ing approaches. An important advantage of micro-cost-
ing is that it considers certain cost components in
greater detail. Gross-costing has the advantage of being
less expensive than micro-costing, but it is less sensitive
and often underestimates certain costs, e.g. personnel
costs for resource intensive patients. Thus, we believe in
this context it is important to provide a high sensitivity
of cost estimates and therefore used a micro-costing
approach [24,25]. For the personnel involved in the
treatment at our outpatient centre we measured the
exact time devoted to an individual patient on an activ-
ity-per-patient basis. To measure the time spent for
each predefined activity, all staff members at the outpa-
tient unit were equipped with stopwatches and required
to document the exact time devoted to each patient.
Prior to data collection, all staff members providing ser-
vices at the outpatient centre were interviewed to deter-
mine principal activities administered by different health
professions using activity-based costing (ABC) metho-
dology. ABC can be regarded as an instrument of the
micro-costing approach. The time-driven ABC metho-
dology that we used allows organizations to determine
actual costs according to the (health care) activities that
originate these costs [26-30]. The actual resource con-
sumption is estimated by taking into account how much
time it takes to carry out each kind of activity and the
costs per time unit associated with the services. ABC is
also a practical tool to identify cost drivers, to evaluate
possible resource or practice changes in the health care
process, and to identify areas where the quality and effi-
ciency of care can be improved [31-33].
Resource utilization not attributable to an individual
outpatient visit and therefore not varying among
patients, such as staff meeting or interdisciplinary coor-
dination, was not measured. For physicians and nurses,
all measured activities were only administered in direct
contact with the patient. All professions (physicians, CF
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nurses, dietitians, physiotherapists and medical assistants
who are either secretaries or doctors’ assistants) were
working only part-time in outpatient treatment and had
to devote the largest amount of their working hours to
inpatients with CF hospitalized at the same health care
facility. Thus, we considered each profession with its
actual working capacity in the outpatient unit. Services
provided by psychologists and social-workers were not
measured because of a lack of personnel. These profes-
sions provide services at the outpatient centre only in
emergency cases. Informed consent was not required
because there were no interventions affecting either
physician’s treatment decisions or the patients.
Cost calculation
Staff costs for outpatient care were calculated in Euros
(€) for the year 2004. Real staff costs were calculated
from the health care service perspective by multiplying
the collected time data by the wages of the respective
care provider professionals. Specifically, the actual time
measured for each activity in minutes was multiplied
with the labour costs per minute (unit costs) of work
for the respective health profession from the perspective
of the health care provider. The unit costs that we used
in our study are based on the gross labour costs
("Arbeitgeberbrutto”) of all personnel employed within a
specific wage group according to the German public ser-
vice salary scheme ("BAT”), which encompasses social
security and pension contributions as well as sick and
annual leave. We used the average gross labour costs for
each occupational category as identified by the study of
Eidt-Koch in a representative university hospital [23].
Classifications
Patients were classified according to age (> 11 years, 11-
18 years, > 19 years), sex and disease severity. Based on
the classification suggested by the CF Foundation,
patients were grouped by three severity levels of their
respiratory function; mild, moderate, and severe corre-
sponding to FEV1 of ≥ 70%, ≥ 40% but < 70%, and <
40%, respectively. A three level severity index was also
applied to all patients based on P. aeruginosa respiratory
colonization and respiratory insufficiency. Patients with
pulmonary hypertension and global respiratory insuffi-
ciency were classified as severe; patients with chronic P.
aeruginosa colonization of the lungs but without pul-
monary hypertension and respiratory insufficiency were
classified as moderate; and patients without chronic
colonization (P. aeruginosa) were classified as mild.
Statistical analysis
Using the two severity categories and the age related
classification, we investigated whether patients could be
grouped into homogenous clusters with respect to mean
costs, and assessed the variance between each group (F-
test). Ordinary least squares (OLS) regression analysis
was performed to determine the impact of FEV1, diag-
nosis-related severity, age and sex on personnel costs
for outpatient management and frequency of visits. The
natural logarithm of costs was used as the dependent
variable for the regression model because the distribu-
tion of “total costs per patient” was skewed. Descriptive
statistics and analysis of the residuals were conducted to
determine the adequacy of the regression analysis. For
the variance and regression analysis, the lung function
was included as the highest individual FEV1 value of all
spirometry results during the study period. All statistical
analyses were performed using STATA (version 10).
Results
Study population
The study included 126 patients visiting the outpatient
centre during the study period. Their demographic and
clinical characteristics are shown in table 1. Of these
subjects the median age was 18 years while ages ranged
from nine months to 55 years. The lung function was
abnormal (FEV1 < 80%) in the majority of adults (80%)
and in half of the younger patients (< 18 years). Twenty
three patients were under six years of age and, thus,
spirometry data were not available for them. Conse-
quently, 103 patients were considered for the evaluation
of FEV1 as a predictive factor for the variation of staff
costs among patients. The mean FEV1 was 63% among
this group, and the impairment of the respiratory func-
tion was mild in 40 patients (FEV1 ≥ 70%), moderate in
41 patients (FEV1 < 70% but ≥ 40%), and severe in 22
patients (FEV1 < 40%). With respect to the diagnosis-
related severity index, 12% of the patients had severe
disease, 52% moderate and 36% mild diseases.
During the six months study period, patients attended
the outpatient centre three times each on average, ran-
ging from one to twelve visits. Of all outpatients 29%
had only one visit, while 30% attended the CF centre
twice and 41% three or more times. A group of 20
patients had six or more outpatient visits during the
study period, of which 14 patients were “moderate”
according to the diagnosis-related severity category.
Cost results and resource use
The mean total staff costs per patient amounted to
€142.3 over six months of outpatient service, ranging
from €22.1 to €669. Validation and plausibility checks
revealed that cost data were about 80% complete. The
costs according to patient age, sex and clinical charac-
teristics are reported in table 1. Among the patients
with total costs above €270 (n = 13), three patients
(21%) had severe levels according to both severity cate-
gories, five (38%) were infants (≤ 1 year) while three
Hollmeyer et al. Health Economics Review 2011, 1:10
http://www.healtheconomicsreview.com/content/1/1/10
Page 3 of 8
(23%) were older than 18 years. For infant patients (n =
9) the average cost was €296.9. Table 2 shows in detail
mean total costs and resource utilization per patient for
the different health professions and specific activities.
Out of the total mean time spent per patient over six
months, 37% was attributable to physicians and 30% to
nursing staff. Resource use with respect to medical assis-
tants, dietitians and physiotherapists was much lower
accounting for 15%, 11% and 8%, respectively. During
each outpatient visit, patients were treated by physicians
and nurses, i.e. a total of 374 times, while the utilization
of medical assistants, dietitians and physiotherapists was
considerably less frequent (80%, 28% and 26%,
respectively).
Analysis of variance
The breakdown of total costs per patient into the cate-
gorical severity models, sex and age groups shows the
highest utilization of outpatient care to be among
patients below 11 years of age, females, and patients
with severe FEV1 and mild diagnosis (table 1). The dif-
ference between the average costs of the group of
patients under 11 years and the average of the group
above that age was statistically significant. Within the
group of children (mean age = 4.2 years), the cost differ-
ence between the mean of infants (≤ 12 months) and
the mean of children aged older than one year to 10
years was also significant (p < 0.01). The total staff costs
per patient were higher for female (€148.9) than for
male patients (€135.8), although statistical significance
was not reached. The differences in total costs for the
severity categories were also not significant.
Regression analysis
As independent variables, the diagnosis-related severity
category had logical correlations with age and FEV1,
while FEV1 was correlated with age. Table 3 shows
regression coefficients for each of the potential predic-
tors of “total staff costs per patient” as the dependent
variable. In the OLS-regression analysis, age showed a
negative significant correlation, whereas sex, FEV1 and
diagnosis-related severity indices were not statistically
significant predictors. Only for adolescents did both
severity categories demonstrate a significant association
with total costs per patient (P < 0.05). Frequency of out-
patient visits was correlated with low costs per visit, and
younger patients tended to visit the outpatient unit
more frequently.
Discussion
In our prospective study on individual utilization of
health care personnel, the average staff costs for six
months of outpatient care were €142.3 per CF patient
from a health care provider’s perspective. Services
Table 1 Study group characteristics, outpatient visits and mean total staff costs per patient per six months, and
results of variance analysis for demographic and clinical parameters
Variable n (%) Outpatient visits Total patients’ staff costs in € (± SD)
Age
children (aged < 11 y) 36 (28.6%) 2.9 181.9 (± 124.3)**
children aged ≤ 1 y (n = 9) 9 (7.1%) 4.4 296.9 (± 169.3)**
children aged > 1-6 y (n = 18) 18 (14.3%) 2.2 147.1 (± 74)
children aged 7-10 y (n = 9) 9 (7.1%) 3.0 136.7 (± 86.2)
adolescents (aged 11-18 y) 30 (23.8%) 3.2 143.7 (± 89.1)
adults (aged 19-55 y) 60 (47.6%) 2.9 117.9 (± 82.1)**
Sex
males 63 (50%) 2.8 135.8 (± 96.4)
females 63 (50%) 3.1 148.9 (± 104.7)
Lung-function-related severity level
mild (FEV1 ≥ 70%) 40 (38.8%) 2.2 113.5 (± 71.2)
moderate (FEV1 < 70% to ≥ 40%) 41 (39.8%) 3.5 132.6 (± 80)
severe (FEV1 < 40%) 22 (21.4%) 3.1 143.8 (± 110.7)
Diagnosis-related severity level
mild (absence of P. aeruginosa) 45 (35.7%) 2.7 162.4 (± 121.5)
moderate (P. aeruginosa colonization) 66 (52.4%) 3.2 128.4 (± 82.1)
severe (pulmonary hypertension and global respiratory insufficiency) 15 (11.9%) 2.9 143.2 (± 101.1)
**p ≤ 0.01 (F-test for each group vs all remaining patients).
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provided by physicians were the biggest contributor to
staff costs (48%). With respect to the impact of outpati-
ent’s demographic and clinical characteristics on staff
costs, age correlated significantly and negatively with
mean total costs per patient. Neither the diagnosis nor
the lung function-related severity model were indepen-
dent risk factors for high staff costs and seem to be
inappropriate criteria for the classification of patients
into homogenous cost groups.
The present study identified higher staff costs and fre-
quency of outpatient visits among younger patients,
especially infants. Increased resource use for infants is
due to the intensive diagnostic workup which usually
takes place during the first year of life. The high fre-
quency of attendance among adolescents reflects the
first infective respiratory exacerbation that usually
occurs during this period of life. Irrespective of disease
factors, younger patients require more time for social
interaction by staff to explain and apply procedures. In
contrast, older patients are more experienced with
respect to self-management and many above 25 years
are likely to have mild disease, thus not requiring a case
management above the routine number of outpatient
visits [8]. Moreover, inpatient admissions of older
Table 2 Mean outpatient staff costs and resources used for a six months study period categorized by different health
professions









Physicians (total) 74.135 (BAT Ib) 91 0.77 70.4 52.1 62
Clinical history and physical
examination
47 0.77 36.2 25.9 31.6
Consultation on diagnosis and
therapy
44 0.77 34.2 26.7 37.6
CF nurses (total) 42.730 (KR. III) 75 0.44 32.9 24.3 28.3
Identification of medical conditions 18 0.44 8.1 7.2 8.0
Assistance to physician 19 0.44 8.4 13.5 13.2
Lung function test 12 0.44 5.1 4.4 4.9
Other nursing services 25 0.44 11.2 8.1 14.1
Medical assistants (total) 40.833 (BAT Vc) 37 0.42 15.5 9.2 20.7
Preparation of tests 6 0.42 2.4 3.2 9.3
Prescriptions and certificates 12 0.42 4.9 3.2 8.6
Accounting 20 0.42 8.3 3.0 17.0
Dietitians (total) 50.007 (BAT IVb) 26 0.52 13.7 18.2 15.4
Nutrition consultation 18 0.52 9.4 13.0 11.6
Information, documentation,
organization
8 0.52 4.3 5.2 5.2
Physiotherapists (total) 46.222 (BAT Vb) 20 0.48 9.8 9.3 16.0
Physiotherapy 18 0.48 8.6 7.6 15.2
Information, documentation,
organization
3 0.48 1.2 2.1 1.5
Total 250 142.3 122.3 100.5
Table 3 Results of ordinal (sex and diagnosis-related severity level) and linear (age and FEV1) regression analysis with
‘Ln (total staff costs per patient)’ as the dependent variable
Independent variable Standardized Coefficient (b) Standard error t-value p-value
Constant 5.079 0.386 13.16 < .0001
Age -0.018 0.007 -2.53 0.013
Sex 0.216 0.134 1.61 0.11
FEV1 -0.005 0.004 -1.33 0.185
Diagnosis-related severity level -0.034 0.144 -0.24 0.812
R-square: 0.08; Adjusted R-square: 0.05; F-value: 2.25
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patients with more severe disease resulted in less fre-
quent outpatient visits during the study period. It is
therefore not surprising that adult patients caused lower
staff costs than younger age groups.
According to our literature review, eight studies
[8,10,13,14,17,18,21,22] estimated resource utilization for
hospital-based CF outpatient services as part of total
annual costs. The cost analysis of six studies was based
on individual resource use under routine care
[8,10,13,14,21,22], while two calculated annual costs
from the aggregate perspective [17,18]. Only two studies
examined different cost categories for outpatient treat-
ment allowing the estimation of costs for health person-
nel [22,23]. Comparison of our findings with those of
other studies addressing CF outpatient costs is not
straightforward as the methodology used, perspective
adopted, and health service utilization and organization
vary. However, some common threads could be
identified.
Eidt-Koch assessed the total resource use for CF out-
patient care including costs for personnel, laboratory
examinations, medication, overhead and infrastructure
[23]. In addition, this study compared the evaluated
costs with the actual reimbursement according to the
official German Remuneration Scheme for Outpatient
Care (EBM) and showed that about half of the costs are
left to the CF centres suggesting that “alternative reim-
bursement schemes should be thought of” [23]. Specifi-
cally, Eidt-Koch’s study explored determinants of costs
by dividing 326 patients in seven CF centres in Germany
according to their age, FEV1 values, certain co-morbid-
ities, and bacterial lung colonization. For all disease
characteristics but FEV1, outpatient costs differed signif-
icantly between the patient groups.
The utilization of personnel, estimated in Eid-Kocht’s
study by patients themselves during one representative
month in 2006, showed somewhat higher staff costs
than in our study. Of the €488 mean total costs per
patient per quarter for CF outpatient care (including
costs for laboratory tests but not drugs), Eidt-Koch
found staff costs of €81.7 for all diagnostic and thera-
peutic activities performed by physicians (€42.4), nurses
(€27.4), physiotherapists (€6) and dietitians (€3.2).
Resource use for services provided by psychologists and
social workers, not considered by our study, were esti-
mated as only €1.2, respectively. Costs identified by our
study were slightly lower (€71.2 per quarter) for similar
activities and when extrapolated to the same time per-
iod, mainly because of fewer resources measured for
lung function tests (€2.6 vs. €24 per quarter). The unex-
pectedly low resource use identified in both studies for
diagnostic and therapeutic activities, which are essential
in CF outpatient care, indicates that services were pro-
vided under enormous time pressure because of
considerable under-staffing and parallel work load with
respect to hospitalized patients with CF. Another study
on hospitalization costs of CF that we implemented
simultaneously at the same health care facility confirmed
that all personnel involved in both inpatient and outpa-
tient care had to apply by far the greatest part of their
working time to the management of inpatients with CF
[15]. In Eidt-Koch’s and our study, outpatient care was
provided by only 2.36 and 1.75 personnel per 100
patients, respectively, which is far below the level
recommended by the European Consensus Conference
(9.6-13.6 personnel). Therefore, staff costs for outpatient
care would probably be much higher if CF centres were
equipped with sufficient personnel who could then
apply treatment in a manner as suggested by the Eur-
opean consensus.
Although not quantitatively measured by our study,
physicians reported that the vast majority of their work
time spent at our CF centre is used for the organization
of outpatient care instead of direct patient contact treat-
ment. Importantly, in Eidt-Koch’s study, staff costs that
were incurred for tasks without involvement of indivi-
dual patients amounted to €134 per patient per quarter,
which is far more than for activities with direct patient
contact. These activities, carried out by physicians,
include the organization and documentation of outpati-
ent and home-based care, quality assurance measures,
interdisciplinary coordination and continuous CF-speci-
fic medical education. Given that in Germany only
about 50% of the actual costs for hospital-based outpati-
ent service utilization are reimbursed [10,23], these addi-
tional activities without patient contact have to be
considered for a cost-covering remuneration.
In a study conducted in the UK in 1990, outpatients’
attendances were registered and time proportions were
allocated to 51 individual patients [22]. Total costs per
patient amounted to £677 per year with health person-
nel utilization by far the largest expenditure, accounting
for 55% (£370), while 34% of the costs were attributable
to medications. Of total staff costs the proportion
incurred by each subgroup of health professionals dif-
fered considerably from our findings (34% for physi-
cians, 33% physiotherapists, 25% social workers, 8%
nurses, 1% dietitians). However, the results of this study
are difficult to compare with ours because of differences
in the methodology for measurement of resource utiliza-
tion and in the organization of health services. Further-
more, the study population included only adults with a
different ratio of mild to severe cases. Other studies
measured total costs of CF outpatient care without spe-
cifying the proportion of personnel costs. In France, the
annual costs of hospital-based outpatient treatment
were estimated as between €354 [13] and €502 [14] in
2000/2001, based on different data gathering
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methodologies. Horvais showed that outpatient costs
including costs for medication and home health care
accounted for 88% of total costs for CF patients in
France [14], where hospital stays have decreased in
favour of home treatment [34]. In the USA, the mean
overall costs of CF outpatient visits were retrospectively
estimated as $1,500 per patient per year from a societal
perspective in 1996 [18]. A study from Canada con-
ducted in the same year found, with $899 annual costs
per patient and $228 per clinic visit, much lower costs
[8]. Compared to the average outpatient visits per
patient identified in our study (6 per year), this number
ranged from 3.3 to about seven visits per year in other
studies [13,17,18,21,22].
The strength of our study lies in the detailed and
long-term measurement of actual resource consumption
at the individual level to calculate staff costs of outpati-
ent CF care. To our knowledge this is the first study
that used an activity-based costing methodology under
conventional treatment conditions to measure staff
costs. The distribution of patient characteristics were
about the same as for the average CF population docu-
mented by the German CF patient registry [35]. This
finding indicates that our results can be extrapolated to
other CF centres in Germany. As difficult decisions
about health care delivery and its funding have to be
made, we believe that our bottom-up analysis provides
reliable information to analyze the cost-effectiveness of
and payment rates for CF outpatient treatment. How-
ever, the basis of unit costs for health professions has
changed considerably since the implementation of our
study. The costs determined in our study have therefore
to be seen in the context of the BAT salary scheme at
that time. For future negotiations on a cost-covering
remuneration of CF outpatient care, only the resource
use in minutes should be considered.
Limitations of our study include the potential underes-
timation of resource utilization because personnel had to
simultaneously provide care for inpatients and outpati-
ents. Staff may also have forgot to measure up to 20% of
activities due to time constraints and emergency visits,
according to plausibility checks. Moreover, we included
in our analysis a comparatively small study population
admitted to only one CF centre which may limit the gen-
eralizability of our results. Another limitation is the
absence of lung function data for 23 patients (< 6 years)
who had to be excluded from the evaluation of FEV1 in
predicting personnel costs. Also, our study may not suffi-
ciently reflect the continued trend from inpatient to out-
patient and home-based therapy which should be
considered when interpreting our results. When we mea-
sured resource use borne by the CF outpatient center, a
trend to move from inpatient to outpatient and home-
based therapy could already be observed, driven in part
by economic pressures [36-39]. Although this trend
towards home-based treatment especially has continued
since, it has not affected the treatment patterns or
amount of routine check-ups for outpatients evaluated by
our study. Moreover, the low staffing level at our centre
has not changed since study implementation.
Conclusions
Our findings on the average financial requirements for
health personnel provide important information for the
remuneration system for CF centres. We have shown that
age is a significant determinant of staff costs for CF outpa-
tient treatment, while severity of disease and lung function
did not predict cost variation. For the remuneration of
outpatient services it seems therefore plausible to stratify
CF patients into homogeneous cost groups according to
age, and create separate reimbursement rates for two or
three age groups. Given that CF centres, including ours,
are substantially understaffed, the relatively low resource
use for personnel identified by our study underestimates
the costs needed for the provision of specialist CF outpati-
ent care according to clinical standards. For a cost-cover-
ing reimbursement and to ensure an accurate quality of
outpatient treatment it is also required to take into
account additional costs due to time-consuming tasks car-
ried out by physicians without direct patient contact.
Moreover, further studies are needed to identify the
further expansion of outpatient and home-based care.
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